Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity
- 1 October 2017
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 263, 172-184
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (RO1 NS051334, 1R41DK108466)
- UNC Eshelman School of Pharmacy
- University Cancer Research Fund
This publication has 82 references indexed in Scilit:
- Transient opening of the perineurial barrier for analgesic drug deliveryProceedings of the National Academy of Sciences, 2012
- Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neuronsFree Radical Biology and Medicine, 2010
- Transport across the Blood-Brain Barrier of Pluronic LeptinThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Recent advances in understanding leptin signaling and leptin resistanceAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity PharmacotherapyObesity, 2009
- Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiersJournal of Controlled Release, 2008
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiesProceedings of the National Academy of Sciences, 2008
- Protein Conjugation with Amphiphilic Block Copolymers for Enhanced Cellular DeliveryBioconjugate Chemistry, 2008
- Leptin inhibits 4-aminopyridine– and pentylenetetrazole-induced seizures and AMPAR-mediated synaptic transmission in rodentsJournal of Clinical Investigation, 2008
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. GeneralizationsJournal of Cerebral Blood Flow & Metabolism, 1985